ArticleMedicine2026
Cronkhite-Canada syndrome after corticosteroid and mesalazine treatment: A case report and 3-year follow-up.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
rationaleCronkhite-Canada syndrome (CCS) is a rare, nonhereditary gastrointestinal polyposis syndrome with known malignant potential. This case report aims to present the clinical course, management, and long-term (3-year) follow-up of a CCS patient, highlighting the discrepancy between symptomatic improvement and endoscopic progression, and to discuss associated carcinogenic risk. PATIENT CONCERNS: A 50-year-old man presented with diffuse abdominal pain of unclear origin, bloody stools, hair loss, melanosis on the hands, and nail dystrophy. DIAGNOSES: Laboratory tests revealed hypoalbuminemia, hypocalcemia, hypokalemia, and positive fecal occult blood. Enteroscopy and subsequent pathological examination confirmed the presence of characteristic intestinal polyps, leading to a diagnosis of CCS.
interventionsThe patient was treated with a continuous regimen of corticosteroids combined with mesalazine. After 1 year of medical therapy, he underwent endoscopic mucosal resection. OUTCOMES: The patient's clinical symptoms improved significantly following treatment. However, endoscopic and pathological findings showed a tendency to deteriorate over time. At the 3-year follow-up, this disparity between clinical well-being and pathological progression persisted. LESSONS: CCS carries a risk of malignant transformation. Even with clinical improvement on long-term corticosteroid and mesalazine therapy, endoscopic progression may occur. Therefore, we recommend intensive endoscopic surveillance every 3 to 6 months following initial diagnosis, maintained for at least the 1st year, as a strategy to mitigate cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.